A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Pfizer412 enrolled

Overview

This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

412

Conditions

Diabetes Mellitus, Type 2

Interventions

PlaceboDRUG

4 matching placebo tablets taken twice a day (BID)

PF-06882961DRUG

Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with T2DM who are treated with metformin and/or diet and exercise * HbA1c greater than or equal to 7% and less than or equal to 10.5% * Total body weight \>50 kg (110 lb) with BMI 24.5 to 45.4 kg/m\^2 Exclusion Criteria: * Any condition possibly affecting drug absorption * Diagnosis of Type 1 diabetes * History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of screening * Any malignancy not considered cured * Personal or family history of MTC or MEN2, or participants with suspected MTC * Acute pancreatitis or history of chronic pancreatitis * Symptomatic gallbladder disease * Known medical history of active proliferative retinopathy and/or macular edema * Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis * Known history of HIV * Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic) * Clinically relevant ECG abnormalities * Positive urine drug test

Locations (83)

Outcomes

Primary Outcomes

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 16

Secondary Outcomes

Percentage of Participants Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 16

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 2

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 4

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 6

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 8

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Holy Trinity Medical Clinic

Harbor City, California, United States

Innovative Clinical Research, Inc.

Harbor City, California, United States

Long Beach Clinical Trials Services, Inc.

Long Beach, California, United States

National Research Institute

Los Angeles, California, United States

Catalina Research Institute, LLC

Montclair, California, United States

Empire Clinical Research

Pomona, California, United States

Rancho Cucamonga Clinical Research

Rancho Cucamonga, California, United States

Encompass Clinical Research

Spring Valley, California, United States

University Clinical Investigators, Incorporated

Tustin, California, United States

San Fernando Valley Health Institute, LLC

Van Nuys, California, United States

...and 73 more locations

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%.

Time frame: Baseline, Week 12

Change From Baseline in Fasting Plasma Glucose at Week 2

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL.

Time frame: Baseline, Week 2

Change From Baseline in Fasting Plasma Glucose at Week 4

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame: Baseline, Week 4

Change From Baseline in Fasting Plasma Glucose at Week 6

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame: Baseline, Week 6

Change From Baseline in Fasting Plasma Glucose at Week 8

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame: Baseline, Week 8

Change From Baseline in Fasting Plasma Glucose at Week 12

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame: Baseline, Week 12

Change From Baseline in Fasting Plasma Glucose at Week 16

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL.

Time frame: Baseline, Week 16

Change From Baseline in Body Weight at Week 2

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 2

Change From Baseline in Body Weight at Week 4

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 4

Change From Baseline in Body Weight at Week 6

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 6

Change From Baseline in Body Weight at Week 8

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 8

Change From Baseline in Body Weight at Week 12

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 12

Change From Baseline in Body Weight at Week 16

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg.

Time frame: Baseline, Week 16

Number of Participants With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Time frame: Baseline up to Week 21

Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol).

Time frame: Baseline Through Week 21

Number of Participants With Treatment Emergent Vital Signs Abnormalities

Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.

Time frame: Baseline through Week 21

Number of Participants With Treatment Emergent ECG Abnormalities

ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2\. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.

Time frame: Baseline Through Week 21